Has the Volume-Based Drug Purchasing Approach Achieved Equilibrium among Various Stakeholders? Evidence from China
Open Access
- 3 April 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (7) , 4285
Abstract
Volume-based drug purchasing by China’s health insurance system currently represents the largest group purchasing organization worldwide. After exchanging the market that accounted for nearly half of the volume of the healthcare system for the ultra-low-price supply of limited drugs, what are the effects on patient and funding burdens, drug accessibility, and clinical efficacy? We aimed to verify the effectiveness of the policy, explore the reasons behind the problem and identify regulatory priorities and collaborative measures. We used literature and reported data from 2019 to 2021 to conduct a stakeholder analysis and health impact assessment, presenting the benefit and risk share for various dimensions. The analysis method was a multidimensional scaling model, which visualized problematic associations. Seventy-nine papers (61 publications and 18 other resources) were included in the study, with 22 effects and 36 problems identified. The results indicated favorable affordability and poor accessibility of drugs, as well as high risk of reduced drug quality and drug-use rationality. The drug-use demand of patients was guaranteed; the prescription rights of doctors regarding clinical drug use were limited; unreasonable evaluation indicators limited the transformation of public hospitals to value- and service-oriented organizations; the sustainability of health insurance funds and policy promotion were at risk; and innovation by pharmaceutical companies was accelerated. The problems associated with high co-occurrence frequencies were divided into the following clusters: cost control, drug accessibility, system rationality, policy fairness, drug quality, and moral hazards. These findings suggested that China has achieved short-term success in reducing the burden on patients and reducing fund expenditure. However, there were still deficiencies in guaranteed supply, quality control, and efficacy tracking. The study offers critical lessons for China and other low- and middle-income countries.Keywords
Funding Information
- National Natural Science Foundation of China (72174207)
This publication has 43 references indexed in Scilit:
- Potential Clinical and Economic Impact of Switching Branded Medications to GenericsAmerican Journal of Therapeutics, 2017
- Generics Substitution, Bioequivalence Standards, and International Oversight: Complex Issues Facing the FDATrends in Pharmacological Sciences, 2016
- Antiretroviral purchasing and prescription practices in Mexico: constraints, challenges and opportunitiesSalud Pública de México, 2015
- Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implicationsFrontiers in Pharmacology, 2014
- A procurement-based pathway for promoting public health: Innovative purchasing approaches for state and local government agenciesJournal of Public Health Policy, 2013
- Critical appraisal skills programmeJournal of Pharmacology and Pharmacotherapeutics, 2013
- Can Price Controls Reduce Pharmaceutical Expenses? A Case Study of Antibacterial Expenditures in 12 Chinese Hospitals from 1996 to 2005International Journal of Health Services, 2013
- Tendering for outpatient prescription pharmaceuticals: What can be learned from current practices in Europe?Health Policy, 2011
- Health Impact Assessment (HIA) for Planners: What Tools Are Useful?Journal of Planning Literature, 2010
- Quality medicines for the poor: experience of the Delhi programme on rational use of drugsHealth Policy and Planning, 2005